antimicrobial stewardship: a concern for all practitioners david j. feola, pharm.d., ph.d., bcps...
TRANSCRIPT
ANTIMICROBIAL STEWARDSHIP:
A CONCERN FOR ALL PRACTITIONERS
David J. Feola, Pharm.D., Ph.D., BCPSAssistant ProfessorUniversity of Kentucky College of Pharmacy
Modern Healthcare, August 7, 2006, page 36 – Protesting infections from MRSA
Hospital Acquired Infections: Pennsylvania 2007
Patients without infection Mortality = 2.0% Length of stay = 4.7 days Average Charge = $37,943
Patients with hospital-acquired infection Mortality = 12.2% Length of stay = 19.7 days Average Charge = $191,872
PA Health Care Cost Containment Council, November 2008
Learning Objectives
1. Summarize the impact of antimicrobial resistance on clinical and economic outcomes in various patient populations.
2. Summarize the goals of antimicrobial stewardship programs in health-systems and the role of health care practitioners in such programs.
3. Explain two core strategies essential for the implementation of antimicrobial stewardship initiatives.
Presentation Overview
Why antimicrobial management is essential
What is antimicrobial stewardship IDSA Guidelines: Definition The Antimicrobial Management Team
How to implement/role of practitioners Recommendations The University of Kentucky experience
Why Stewardship is Needed
Antimicrobial resistance results in Increased morbidity/mortality Increased healthcare costs
Practices in antimicrobial use often inadequate, not routinely implemented Up to 50% antimicrobial prescribing
inappropriate Causal relationship between antimicrobial
use and emergence of resistance
A Disturbing Trend
1930 1940 1950 1960 1970 1980 1990 2000 2010
Sulfa, BL, AG, Chloramphenicol
TCN, MAC, Vanc, RIF, FQ, TMP
No new classes. Modification of existing agents.
LZD, DAP,TIG
CBP; DAL;New Entities
Limited
PCN-resistant S. aureus
MRSA
VRE
VISA in 7 states
VRSA
LZD-R S. aureus
MDR Pseudomonas and Acinetobacter, metallo-beta-lactamases, carbapenemases
Half of US and Japanese companies END drug discovery
The Critical Balance
Importance of appropriate empiric therapy
Effect of broad-spectrum therapy on resistance
Mortality increases when initial therapy is inappropriate
Resistance increases when broad-spectrum
agents are needed; Resistance has a
negative impact on outcomes
“Collateral damage”
Appropriate Initial Therapy Affects Outcomes
*Difference in mortality not significant. LOS significantly increased
Importance of appropriate empiric therapy
Effect of broad-spectrum therapy on resistance
Antimicrobial Use and Resistance Changes in use parallel changes in resistance Resistance higher in healthcare-associated
infections Patients with resistant infections more likely
to have received prior antimicrobials Hospital areas of highest resistance
associated with highest antimicrobial use Increased duration of therapy increase
likeliness of colonization with resistant organisms
Shales DM et al. CID 1997;25:584-99.
ESBL Production and Outcomes
Non-urinary tract isolates of Klebsiella, E. coli
Length of stay 21 days vs. 11 days
(P=0.006) Clinical success
48% vs. 86% (P=0.027)
Lee, et al. Inf Cont Hosp Epi 2006;27:1226-32
Effect of broad-spectrum therapy on resistance
and outcomes
Importance of appropriate empiric therapy
MRSA and Outcomes
MRSA vs. MSSA bacteremia Clinical Failure:
59.6% vs. 33% (P<0.001) Length of Stay (infection-
related):20.1 vs. 13.7 days (P<0.001)
Mortality (infection-related):30.6% vs. 15.3% (P=0.001)
Lodise T and McKinnon P. Diag Microbiol Inf Dis 2005;52.
Effect of broad-spectrum therapy on resistance
and outcomes
Importance of appropriate empiric therapy
VRE and Outcomes
VRE bacteremia Decreased survival:
24% vs. 59% Length of Stay:
34.8 vs. 16.7 days Attributable cost: $27,190
VRE bloodstream meta-analysis Mortality increase: 30%
Stoser V et al. Arch Int Med 1998;158:522-7
DiazGranados CA et al. CID 2005;41:327-33.
Salgado CD et al. Inf Contr Hosp Epid 2003;24:690-8.
Effect of broad-spectrum therapy on resistance
and outcomes
Importance of appropriate empiric therapy
P. aeruginosa Resistance
Obritsch MD, et al. Antimicrob Agents Chemother. 2004;48:4606-4610
Correlation: Use and Resistance
Lepper PM et al. Antimicrob Agents Chemother 2002;46:2920-5.Lepper PM et al. Antimicrob Agents Chemother 2002;46:2920-5.
Fluoroquinolones
Ciprofloxacin—selection of resistant isolates when appropriate pharmacodynamic parameters are not met (AUC/MIC) Pseudomonas aeruginosa (All
fluoroquinolones) Methicillin-susceptible Staph aureus Streptococcus pneumoniae
Garcia-Rey C et al. Clin Microbial Infect 2006;12:55-66Jacobi GA. Clin Infec Dis 2005;41:S120-6Cook PP et al. J Hosp Infect 2006:54:341-58.
Pseudomonas aeruginosaCiprofloxacin Resistance Trends (1989-1999)
Source: The Surveillance Network (TSN), Focus TechnologiesAnd for 2003, NNIS Survey. AJIC 2003
3rd Generation Cephalosporins Cause/associated with several different
problems in the hospital (oximinocephalosporins) Extended-spectrum beta-lactamases Selection of stably derepressed isolates in
SPACE bacteria Selection of vancomycin-resistant
enterococcus – particularly E. faecium Contribution to MRSA Increased cases of Clostridium difficile
associated diarrhea/colitisDancer SJ. J Antimcirobial Chemother 2001; 48: 463-478
Carbapenems: Emerging Resistance
Meropenem and P. aeruginosa Up-regulation of MexA-MexB-Oprm (efflux
pump) Loss of the OprD protein (porin channel)
Both mutations needed for resistance development MIC 0.12–0.5 µg/ml (before mutation) MIC 2-4 µg/ml (with one mutation) MIC >8 µg/ml (with both mutations)
Livermore D. JAC 2001; 47: 247-250
Perilous Cycle: KPC Example
Resistant Pathogen
Unknown pathogen
OximinocephalosporinsESBL production
ESBL-producing E. coli,K. pneumo, SPACE
ESBL-producingbacteria
CarbapenemsCarbapenemase development
KPC
KPC-producinginfection
?????
Economic Impact of Resistance
S. aureus bacteremia Methicillin resistance: 100% greater cost of
therapy
Klebsiella and E. coli infections ESBL production: 66% greater cost of
therapy
Pseudomonas aeruginosa infections Imipenem resistance: 68% greater cost of
therapyLodise T and McKinnon P. Diag Microbiol Inf Dis 2005;52.
Lee, et al. Inf Cont Hosp Epi 2006;27:1226-32.
Lautenbach, et al. Inf Cont Hosp Epi 2006;27:893-90.
Definition: Antimicrobial Stewardship Infection control plus antimicrobial
management Appropriate antimicrobial selection, dosing,
route, and duration System selection of antimicrobials that cause
the least collateral damage MRSA ESBLs Clostridium difficille Stable derepression Metallo-beta-lactamases and other carbapenemases VRE
Guideline Resources
IDSA and SHEA Guidelines for Developing an Institutional Program to
Enhance Antimicrobial Stewardship Dellit TH et al. CID 2007;44:159-77
Centers for Disease Control Management of Multidrug-Resistant Organisms in
Healthcare Settings http://www.cdc.gov/ncidod/dhqp/pdf/ar/
mdroGuideline2006.pdf
ASM and SHEA Antimicrobial Resistance Prevention Initiative—An Update Moellering RC et al. Am J of Inf Contr 2007;35:S1-23
Role of Infection Control
Infection control trumps everything else Hand hygiene – must have hand washing
police Barrier precautions
Devotion to all aspects of strict infection control Nursing staff Medical staff Medical staff leadership
Infection Control – is it cost effective?
Infection Cost Savings VAP $25,072 Bacteremia $23,242 Surgical Site infection $10,443 Urinary Tract Infection $ 758
Anderson, et al. Infect Control Hosp Epidem 2007;28:767-73
Goals of Antimicrobial Stewardship
Primary goal Optimize clinical outcome/minimize unintended
consequences of antimicrobial use Unintended consequences:
Toxicity Selection of pathogenic organisms Emergence of resistant pathogens
Secondary goal Reduce healthcare costs without adversely
impacting quality of care
Core Members of the Team
Infectious disease physician (Director or Co-director)
Clinical pharmacist with infectious disease training (Co-director or core member)
Other members of the team Microbiologist Information system specialist Infection control professional Hospital epidemiologist
IDSA Grading System for Ranking Recommendations in Clinical Guidelines
Kish MA et al. CID 2001; 32: 851 - 4
Category, Grade Definition
Strength of recommendationA
Good evidence to support
B Moderate evidence to support
C Poor evidence to support
Quality of evidenceI ≥ 1 randomized, controlled trials
II ≥ 1 clinical trial unrandomized, cohort or case-controlled studies, dramatic results from uncontolled experiments
III Opinion of experts, clinical experience, descriptive studies
Active Core Strategies
Prospective audit with intervention and feedback to reduce inappropriate antimicrobial use (A-I)
Formulary restriction and pre-authorization leading to reductions in antimicrobial use and cost (A-II)
NOTE – neither of these strategies are mutually exclusive
Assessments
Antimicrobial consumption Defined daily dose Cost Days of treatment
Antimicrobial adverse events Resistance patterns/development Intervention monitoring
Patel D et al. Exp Rev Anti Infect Ther 2008; 6:209-22
Assessments
Clinical outcomes measurements Antimicrobial appropriate Cure vs. failure
Clinical Microbiologic Superinfections Reinfection
Resistance development
Fishman N. Am J Inf Contr 2006;34:S55-63
Elements for Consideration and Prioritization
Parenteral to oral conversion (A-I) When the patient’s condition allows
Decrease length of stay Decrease healthcare costs
Development of clinical criteria and guidelines allowing conversion to use of oral agents (A-III)
Elements for Consideration and Prioritization
Streamlining or de-escalation therapy (A-II) Based on culture results and elimination of
redundant therapy Decreases antimicrobial exposure and cost
Dose optimization (A-II) Based on PK/PD parameters and includes
patient characteristics, causative organism, site of infection, in addition to PK/PD characteristics of the drug
Elements for Consideration and Prioritization
Educational programs, active intervention (A-III, B-II) Provides foundation of knowledge
Guidelines and clinical pathways – seek multi-disciplinary involvement and approval (A-I) Incorporate local antimicrobial resistance
patterns (A-I) Provide education and feedback to
practitioners (A-III)
Elements for Consideration and Prioritization
Antimicrobial order forms (B-II) Shown to be effective component of the program
and can facilitate implementation into practice
Combination therapy Insufficient data for routine use (C-II) Has a role to increase coverage in empiric
therapy in patients at risk for multi-drug resistant pathogens
Antimicrobial cycling – is not recommended because of insufficient data (no ranking)
Research Priorities/Future Directions
Antimicrobial Cycling
Validation of mathematical models of resistance
Long-term impact of formulary restrictions
Focusing interventions on “collateral damage issues”
Development of more rapid susceptibility tests
Bad bugs/no drugs – stimulate research
Counteract inappropriate detailing
Critical Success Factors Identified
Collegial and educational relationship Daily review of antimicrobial orders by a
consistent accountable team Support of hospital/medical leadership FTE’s dedicated to program (Pharm.D. and
MD) Development of criteria and guidelines for
anti-infective use Formulary restriction Education of prescribers to insure compliance
STAAR
The Strategies to Address Antimicrobial Resistance Act Develop an Office of Antimicrobial Resistance within
DHHS Coordinate a plan for addressing the problem of
antimicrobial resistance Create Public Health Advisory Board Create Antimicrobial Resistance Research and Strategic Plan
Collection of antimicrobial drug utilization data in humans and animals
Development of a clinical research and public health network Award grants
Endorsed by SIDP, IDSA, SHEA, PIDS, AMA, APHA, APIC, NFID, APUA, and ACP
Control prescribing Vancomycin Reduce 3rd generation cephalosporin use Select a single fluoroquinolone (not ciprofloxacin) Select a single carbapenem
Antimicrobial Management Team Physician , Pharmacist hired (2001) Data collection
Pathways for empirical antimicrobial use
ICU specific antibiograms
Minimize the use of TPN
The University of Kentucky Experience: Antimicrobial Stewardship 1998-2008
Martin, et al. AJHP 2005; 62: 732 - 738
Prevalence of MRSAUniversity of Kentucky Hospital
AMT program begins
Antibiotic Cost/Patient DayUniversity Hospital Consortium: Top 7
InstitutionCost/Patient
Day Yale New Haven* 10.75
University of Kentucky* 11.25
Northeast UHC Hospital* 11.33
Southeast UHC Hospital 12.06
UC Davis* 12.33
Northeast UHC Hospital* 15.65
Northeast UHC Hospital* 15.69
* Active Antimicrobial Team – ID Physician and Pharmacist
AMT versus No AMT
UHC antibiotic cost/patient day No antimicrobial management team -
$19.80 With antimicrobial management team -
$12.83
$19.80 - $12.83 = $6.97/patient day UKMC in 2004 had 114,983 patient days Est. cost savings = $801,438/year
Antimicrobial Costs at UK
$8,188,456
$1,793,723
UKMC: Current Challenges
Linezolid prescribing No data proving better than vancomycin Multinational trial in progress
Acinetobacter Clonal outbreak Back to baseline—rolling ICU shutdown
MRSA Rates increasing CA-MRSA responsible
Where to Begin
Chief of ID, Director of Pharmacy Develop initial budget proposal Present to hospital administration Include financial and microbiology goals
Form Antimicrobial Subcommittee to P&T
Hire physician and pharmacist Develop practice guidelines/pathways Buy in and implement
Summary and Conclusions
Antimicrobial Stewardship programs show great promise and offer new opportunities for patient care and cost impact
Recommendation by both IDSA/ASHP and the CDC offer firm foundations to obtain support and funding for antimicrobial stewardship programs
Huge opportunity for advancement of clinical pharmacy practice